Merck Patent Gesellschaft MIT Beschrankter Haftung

Merck Patent Gmbh

Merck Patent Gesellschaft MIT Beschraenkter Haftung

Merck Patent Gesellschaft

Merck Patent Gesellschaft MIT Beschr&auml;nkter Haftung

Pierre Schelling

Norbert Beier

Maria Christadler

Werner Mederski

Klaus-Otto Minck

Ingeborg Lues

Rochus Jonas

Dieter Dorsch

Hans-Michael Eggenweiler

Franz-Werner Kluxen

Mathias Osswald

Michael Wolf

Thomas Ehring

Johannes Sombroek

Manfred Baumgarth

Joachim Leibrock

Andreas Bathe

Michael Gassen

Jonas Rochus

Thorsten Hartig

Hans-Micahel Eggenweiler

Matthias Osswald

Harry Schwartz

Hydrazono-malonitrile derivatives of the formula (I) in which R, R, R, Rand Rhave the meanings given in Claimact as phosphodiesterase IV inhibitors and can be employed for the treatment of osteoporosis, tumors, cachexia, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, inflammatory processes, allergies, asthma, autoimmune diseases, myocardial diseases and AIDS. 

Hydrazono-malonitriles

Triazine derivatives of the formula (I) and physiologically acceptable salts and solvates thereof, in which R, R, A and Rare as defined in Claim, exhibit phosphodiesterase IV inhibition and can be employed for the treatment of allergic diseases, asthma, chronic bronchitis, atopic dermatitis, psoriasis and other skin diseases, inflammatory diseases, autoimmune diseases, such as, for example, rheumatoid arthritis, multiple sclerosis, Crohn's disease, diabetes mellitus or ulcerative colitis, osteoporosis, transplant rejection reactions, cachexia, tumour growth or tumour metastases, sepsis, memory disorders, atherosclerosis and AIDS, furthermore for inhibiting the formation of TNF&#x3b1;. 

4-(benzylidene-amino)-3-(methylsulfanyl)-4h-(1,2,4)triazin-5-one derivatives having a PDE-IV inhibiting and TNF-antagonistic effect for the treatment of cardiac diseases and allergies

Aryl oxime derivatives of the formula (I), in which R, R, R, X and B are as defined in Claim, act as phosphodiesterase IV inhibitors and can be employed for the treatment of osteoporosis, tumours, cachexia, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, inflammatory processes, allergies, asthma, autoimmune diseases, myocardial diseases and AIDS. 

Aryl oximes

Pyrimidine derivatives of the formula (I) and physiologically acceptable salts thereof, in which R, R, R, R, W, X, Y and Z are as defined in claimexhibit phosphodiesterase V inhibition and can be employed for the treatment of diseases of the cardiovascular system and for the treatment and/or therapy of potency disorders 

Pyrimidine derivatives

The present invention relates to 2-aminomethylthieno[2,3-d]pyrimidines of the general formula (I) in which the radicals Rto Rhave the meaning indicated in the text. The compounds show phosphodiesterase V inhibition and can be employed for the treatment of conditions of the cardiovascular system and for the treatment of potency disorders.

2-Aminoalkyl-thieno[2,3-d]pyrimidines

Hydrazono-malonitrile derivatives of the formula (I) in which R, R, R, Rand Rhave the meanings given in Claimact as phosphodiesterase IV inhibitors and can be employed for the treatment of osteoporosis, tumours, cachexia, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, inflammatory processes, allergies, asthma, autoimmune diseases, myocardial diseases and AIDS 

Aryl oxime derivatives of the formula (I), in which R, R, R, X and B are as defined in claim, act as phosphodiesterase IV inhibitors and can be employed for the treatment of osteoporosis, tumours, cachexia, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, inflammatory processes, allergies, asthma, autoimmune diseases, myocardial diseases and AIDS 

The present invention relates to 5-aminomethylpyrazolo[4,3-d]pyrimidines of the general formula (I) in which the radicals Rto Rhave the meaning indicated in the text. The compounds show phosphodiesterase V inhibition and can be employed for the treatment of conditions of the cardiovascular system and for the treatment of potency disorders.

5-aminoalkyl-pyrazolo[4,3-d]pyrimidines with a phosphodiesterase v-inhibiting effect

The invention relates to compounds of the formula (I) in which R, Eand X are as defined above.

Sulfamidothienopyrimidines

Thienopyrimidines as phosphodiesterase inhibitors

Thienopyrimidines of the formula (I) and their physiologically acceptable salts, in which R , R and X are as defined in claim 1, exhibit phosphodiesterase V inhibition and can be employed for the treatment of illnesses of the cardiovascular system and for the treatment and/or therapy of impotence.

Thienopyrimidines

Pyrazolo &lsqb;4,3-d&rsqb;pyrimidines

Condensed thienopyrimidines with phosphodiesterase-v inhibiting action

The thienopyrimidines of the formula (I) and their physiologically compatible salts display a phosphodiesterase V inhibiting activity and can be used for treating diseases of the cardiovascular system and for treatment and/or therapy of erectile dysfunction.

Growing community of inventors

Muehltal, Germany

Pierre Schelling